Services
Helping biopharmas identify how and when China makes sense—launching via Hong Kong to protect IP and capital while accelerating R&D, manufacturing and clinical.
Entering the PRC market without the right structure exposes IP and capital to unnecessary risk. We map IP-safe HK and PRC entity structures, benchmark Free Trade Zone incentives and tailor regional pathways to your modality.
Misaligned entity, tax and governance decisions can limit future financing and commercialization. We design integrated business strategies aligned to investor expectations and long-term growth.
Capital inefficiency and poor forecasting stall market entry. We build 12–36 month financial models that align funding sources, vendor strategies and cash discipline. We also provide tax impact and transfer pricing analysis.
Noncompliant facilities delay programs and increase regulatory risk. We secure compliant sites, equipment and layouts to support clinical trials and GMP readiness from Day 1.
Regulatory gaps can halt operations before they begin. We inventory compliance needs and special permits and validate biosafety requirements to enable compliant operations.
Inefficient material flows disrupt R&D and clinical timelines. We optimize licensing pathways, logistics partners and cross-border material movement.
Early hiring missteps create quality and execution risk. We assemble local teams, implement quality systems and support scientist collaborations.
Cross-border execution fails without consistent oversight. We provide bilingual program management across all phases with ongoing finance, accounting, HR and legal support for seamless delivery and operations.
*Powered by our ecosystem of talent agencies, brokers, law firms, universities, facilities, government officials and UHY offices across Hong Kong and PRC.